Dataset Information


Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats.

ABSTRACT: Traumatic brain injury is a leading cause of death and disability around the world. So far, drugs are not available to repair brain damage. Human mesenchymal stem cell (hMSC) transplantation therapy is a promising approach, although the inflammatory microenvironment of the injured brain affects the efficacy of transplanted hMSCs. We hypothesize that reducing the inflammation in the cerebral microenvironment by reducing pro-inflammatory chemokines prior to hMSC administration will improve the efficacy of hMSC therapy. In a rat model of lateral fluid percussion injury, combined pioglitazone (PG) and hMSC (combination) treatment showed less anxiety-like behavior and improved sensorimotor responses to a noxious cold stimulus. Significant reduction in brain lesion volume, neurodegeneration, microgliosis and astrogliosis were observed after combination treatment. TBI induced expression of inflammatory chemokine CCL20 and IL1-β were significantly decreased in the combination treatment group. Combination treatment significantly increased brain-derived neurotrophic factor (BDNF) level and subventricular zone (SVZ) neurogenesis. Taken together, reducing proinflammatory cytokine expression in the cerebral tissues after TBI by PG administration and prior to hMSC therapy improves the outcome of the therapy in which BDNF could have a role.


PROVIDER: S-EPMC6754424 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7248546 | BioStudies
2018-01-01 | S-EPMC6079305 | BioStudies
2015-01-01 | S-EPMC4291210 | BioStudies
2013-01-01 | S-EPMC3734670 | BioStudies
2020-01-01 | S-EPMC7325955 | BioStudies
2018-01-01 | S-EPMC6434451 | BioStudies
2017-01-01 | S-EPMC5404305 | BioStudies
1000-01-01 | S-EPMC5599915 | BioStudies
2019-01-01 | S-EPMC6544928 | BioStudies
2017-01-01 | S-EPMC5311054 | BioStudies